132 related articles for article (PubMed ID: 37406290)
21. Immunohistochemistry in Gynecologic Pathology: An Example-Based Practical Update.
Buza N; Hui P
Arch Pathol Lab Med; 2017 Aug; 141(8):1052-1071. PubMed ID: 28745567
[TBL] [Abstract][Full Text] [Related]
22. Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scanners.
Salama AM; Hanna MG; Giri D; Kezlarian B; Jean MH; Lin O; Vallejo C; Brogi E; Edelweiss M
Mod Pathol; 2022 Jan; 35(1):52-59. PubMed ID: 34518629
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor, progesterone receptor, HER2/neu, P53 and Ki-67 status of male breast carcinomas in Pakistan.
Jamal S; Mushtaq H; Mubarik A; Malik TM
Asian Pac J Cancer Prev; 2009; 10(6):1067-70. PubMed ID: 20192585
[TBL] [Abstract][Full Text] [Related]
24. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
[TBL] [Abstract][Full Text] [Related]
25. p53 as a marker of prognosis in African-American women with breast cancer.
Dookeran KA; Dignam JJ; Ferrer K; Sekosan M; McCaskill-Stevens W; Gehlert S
Ann Surg Oncol; 2010 May; 17(5):1398-405. PubMed ID: 20049641
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
28. Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment.
Wu H; Guan S; Sun M; Yu Z; Zhao L; He M; Zhao H; Yao W; Wang E; Jin F; Xiao Q; Wei M
PLoS One; 2015; 10(5):e0126128. PubMed ID: 25961581
[TBL] [Abstract][Full Text] [Related]
29. Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer.
Chen M; Wu J; Liu D; Chen W; Lin C; Andriani L; Ding S; Huang O; He J; Chen X; Chen W; Li Y; Shen K; Zhu L
Clin Breast Cancer; 2022 Feb; 22(2):e147-e156. PubMed ID: 34244052
[TBL] [Abstract][Full Text] [Related]
30. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
[TBL] [Abstract][Full Text] [Related]
31. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
[TBL] [Abstract][Full Text] [Related]
32. Correlation of PKM2 Expression With HER2/neu and Additional Breast Cancer Biomarkers and its Prognostic Significance.
Al-Qudah MA; Al-Keilani MS; Obeidat M; Haddad HK; Bdeir R; Samman LM
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):363-370. PubMed ID: 37212690
[TBL] [Abstract][Full Text] [Related]
33. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nwafor CC; Keshinro SO
Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
[TBL] [Abstract][Full Text] [Related]
34. Expressional correlation of human epidermal growth factor receptor 2, estrogen/progesterone receptor and protein 53 in breast cancer.
Panahi M; Saki N; Ashourzadeh S; Rahim F
Asian Pac J Cancer Prev; 2013; 14(6):3699-703. PubMed ID: 23886168
[TBL] [Abstract][Full Text] [Related]
35. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
Kinsella MD; Nassar A; Siddiqui MT; Cohen C
Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
[TBL] [Abstract][Full Text] [Related]
36. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
[TBL] [Abstract][Full Text] [Related]
37. Analytical and clinical performance of progesterone receptor antibodies in breast cancer.
Calhoun BC; Mosteller B; Warren D; Smith M; Jordi Rowe J; Lanigan CP; Mrazeck KC; Walker E; Newell AH; Jones R
Ann Diagn Pathol; 2018 Aug; 35():21-26. PubMed ID: 29758480
[TBL] [Abstract][Full Text] [Related]
38. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Howell SJ; Wardley AM; Armstrong AC
J Natl Cancer Inst; 2009 Dec; 101(24):1730; author reply 1730-1. PubMed ID: 19893007
[No Abstract] [Full Text] [Related]
39. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
40. In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases.
Giuliani S; Ciniselli CM; Leonardi E; Polla E; Decarli N; Luchini C; Cantaloni C; Gasperetti F; Cazzolli D; Berlanda G; Bernardi D; Pellegrini M; Triolo R; Ferro A; Verderio P; Barbareschi M
Virchows Arch; 2016 Jul; 469(1):45-50. PubMed ID: 27097809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
